Tocilizumab Fails Late-Stage Trial for COVID-19
ZURICH (Reuters)—Roche’s attempt to retool its rheumatoid arthritis drug Actemra/RoActemra (tocilizumab) to treat patients hospitalized with severe COVID-19-related pneumonia has failed in a late-stage trial, the Swiss company said on July 29. Roche launched the 330-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic. The... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: John Revill Tags: Drug Updates COVID-19 Roche tocilizumab Source Type: research
More News: Actemra | Arthritis | COVID-19 | Pandemics | Pneumonia | Rheumatoid Arthritis | Rheumatology | Switzerland Health